Literature DB >> 16388674

Study on the base-catalyzed reverse vinylogous aldol reaction of (4abeta,5beta)-4,4a,5,6,7,8-hexahydro-5-hydroxy-1,4a-dimethylnaphthalen-2(3H)-one under Robinson annulation conditions.

Joshua N Payette1, Tadashi Honda, Hidenori Yoshizawa, Frank G Favaloro, Gordon W Gribble.   

Abstract

[reaction: see text] We have proposed a pathway for the base-catalyzed reverse vinylogous aldol reaction of (-)-(4abeta,5beta)-4,4a,5,6,7,8-hexahydro-5-hydroxy-1,4a-dimethylnaphthalen-2(3H)-one [(-)-8] under Robinson annulation conditions. For confirmation, 4-(2,6-dimethyl-3-oxocyclohex-1-enyl)butanal (11) and 4-(2,6-dimethyl-5-oxocyclohex-1-enyl)butanal (12), both of which potentially produce enolate I, were synthesized regioselectively. Unexpectedly, 11 gave a complex mixture, including only a trace amount of (+/-)-8 (less than 5% yield), under these basic conditions. To the contrary, 12 cleanly afforded (+/-)-8 in 66% yield. This result provides evidence for our proposed mechanism of the above reaction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16388674      PMCID: PMC2597452          DOI: 10.1021/jo0520036

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  2 in total

1.  Design and synthesis of tricyclic compounds with enone functionalities in rings A and C: a novel class of highly active inhibitors of nitric oxide production in mouse macrophages.

Authors:  Frank G Favaloro; Tadashi Honda; Yukiko Honda; Gordon W Gribble; Nanjoo Suh; Renee Risingsong; Michael B Sporn
Journal:  J Med Chem       Date:  2002-10-24       Impact factor: 7.446

2.  Efficient synthesis of (-)- and (+)-tricyclic compounds with enone functionalities in rings A and C. A novel class of orally active anti-inflammatory and cancer chemopreventive agents.

Authors:  Tadashi Honda; Frank G Favaloro; Tomasz Janosik; Yukiko Honda; Nanjoo Suh; Michael B Sporn; Gordon W Gribble
Journal:  Org Biomol Chem       Date:  2003-10-31       Impact factor: 3.876

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.